Condition: Severe Asthma · Sponsor: AstraZeneca
This study is an observational multicenter cross-sectional study. Planned study population consists of 5 000 adult patients with uncontrolled SA receiving treatment according to standard of care (except biologics). Planned number of study site is 50 outpatient centers with experience of uncontrolled SA treatment in about 50 regions of Russia (in order to describe characteristics of patients with uncontrolled SA in different regions in the most comprehensive way). This non-interventional study does not imply any intervention into a routine clinical practice, and does not provide for any diagnostic and therapeutic procedures other than those used in routine practice.
This description comes directly from the study's public registry record.
AstraZeneca Clinical Study Information Center · 1-877-240-9479 · information.center@astrazeneca.com
Always discuss trial participation with your own doctor first.
| Research Site | Astrakhan, Russia | Recruiting |
| Research Site | Barnaul, Russia | Recruiting |
| Research Site | Blagoveshchensk, Russia | Recruiting |
| Research Site | Bryansk, Russia | Recruiting |
| Research Site | Chelyabinsk, Russia | Recruiting |
| Research Site | Gatchina, Russia | Recruiting |
| Research Site | Irkutsk, Russia | Recruiting |
| Research Site | Izhevsk, Russia | Recruiting |
| Research Site | Kazan', Russia | Recruiting |
| Research Site | Kemerovo, Russia | Recruiting |
| Research Site | Khabarovsk, Russia | Recruiting |
| Research Site | Krasnodar, Russia | Recruiting |
+ 25 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06472310